The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Anti‐donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?
Open accessAbstract
Mesenchymal stem (stromal) cells (MSCs) have potent anti‐inflammatory/immunosuppressive properties which underlie much of their therapeutic potential. This fact has led to the widely accepted belief that MSCs from genetically unrelated individuals (allogeneic (allo)‐MSCs) can be used therapeutically with equal efficacy to autologous MSCs and without triggering the donor‐specific immune responses that are typically associated with allo‐transplants. In this article, we critically review available experimental data to determine whether good in vivo evidence exists in support of the ‘immune privileged’ status of allo‐MSCs. We also examine published studies regarding the immunogenicity of allo‐MSCs following activation (‘licensing’) by inflammatory stimuli or following differentiation. Among the identified studies which have addressed in vivo immunogenicity of allo‐MSCs, there was substantial variability as regards experimental species, disease model, route of MSC administration, cell dose and stringency of the immunological assays employed. Nonetheless, the majority of these studies has documented specific cellular (T‐cell) and humoral (B‐cell/antibody) immune responses against donor antigens following administration of non‐manipulated, interferon‐γ‐activated and differentiated allo‐MSCs. The consequences of such anti‐donor immune responses were also variable and ranged from reduced in vivo survival of allo‐MSCs with accelerated rejection of subsequent allogeneic transplants to apparent promotion of donor‐specific tolerance. On the basis of these findings and on existing knowledge of allo‐antigen recognition from the field of transplant immunology, we propose that the concept of the immune privileged nature of allo‐MSCs should be reconsidered and that the range and clinical implications of anti‐donor immune responses elicited by allo‐MSCs be more precisely studied in human and animal recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Németh, K., Leelahavanichkul, A., Yuen, P. S. T., Mayer, B., Parmelee, A., Doi, K., Robey, P. G., Leelahavanichkul, K., Koller, B. H., Brown, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1905 · Cited by 2,364
Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816
Rejection of the Kidney Allograft
Nankivell, B. J., & Alexander, S. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0902927 · Cited by 605
Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications
Ghannam, S., Bouffi, C., Djouad, F., Jorgensen, C., & Noël, D. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt2 · Cited by 507
Mechanisms of Rejection: Current Perspectives
Wood, K. J., & Goto, R. (2012) · Transplantation · doi:10.1097/tp.0b013e31823cab44 · Cited by 369
Cited by
Mesenchymal stem cells: immune evasive, not immune privileged
Ankrum, J. A., Ong, J. F., & Karp, J. M. (2014) · Nature Biotechnology · doi:10.1038/nbt.2816 · Cited by 1,531
Mesenchymal Stem Cell-derived Extracellular Vesicles: Toward Cell-free Therapeutic Applications
Rani, S., Ryan, A. E., Griffin, M. D., & Ritter, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.44 · Cited by 1,227
Self-citationHarrell, C., Fellabaum, C., Jovicic, N., Djonov, V., Arsenijevic, N., & Volarevic, V. (2019) · Cells · doi:10.3390/cells8050467 · Cited by 501
Konala, V. B. R., Mamidi, M. K., Bhonde, R., Das, A. K., Pochampally, R., & Pal, R. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2015.10.008 · Cited by 451
MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation
Kean, T. J., Lin, P., Caplan, A. I., & Dennis, J. E. (2013) · Stem Cells International · doi:10.1155/2013/732742 · Cited by 433
L. Ramos, T., Sánchez-Abarca, L. I., Muntión, S., Preciado, S., Puig, N., López-Ruano, G., Hernández-Hernández, Á., Redondo, A., Ortega, R., Rodríguez, C., et al. (2016) · Cell Communication and Signaling · doi:10.1186/s12964-015-0124-8 · Cited by 312
The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy
Zhang, J., Huang, X., Wang, H., Liu, X., Zhang, T., Wang, Y., & Hu, D. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0240-9 · Cited by 310
Reconstructed Stem Cell Nanoghosts: A Natural Tumor Targeting Platform
Toledano Furman, N. E., Lupu-Haber, Y., Bronshtein, T., Kaneti, L., Letko, N., Weinstein, E., Baruch, L., & Machluf, M. (2013) · Nano Letters · doi:10.1021/nl401376w · Cited by 273
Álvaro-Gracia, J. M., Jover, J. A., García-Vicuña, R., Carreño, L., Alonso, A., Marsal, S., Blanco, F., Martínez-Taboada, V. M., Taylor, P., Martín-Martín, C., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208918 · Cited by 264
Saether, E. E., Chamberlain, C. S., Leiferman, E. M., Kondratko-Mittnacht, J. R., Li, W. J., Brickson, S. L., & Vanderby, R. (2014) · Stem Cell Reviews and Reports · doi:10.1007/s12015-013-9479-7 · Cited by 38
Clinical application of stem cell in patients with end-stage liver disease: progress and challenges
Tao, Y.-C., & Chen, E.-Q. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.153 · Cited by 15
Metadata
- Authors
- Griffin, M. D., Ryan, A. E., Alagesan, S., Lohan, P., Treacy, O., & Ritter, T.
- Venue
- Immunology & Cell Biology
- Publisher
- Wiley
- Published
- 2012-12-04
- Volume
- 91
- Issue
- 1
- Pages
- 40-51
- ISSN
- 0004-945X (ISSN-L)
- 0818-9641
- 1440-1711
- OpenAlex
- W2033597878
- Cited by
- 249
- References
- 5
- FWCI
- 10.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.